AbbVie To Acquire West Pharmaceuticals' Tempe Device Facility To Expand Drug Delivery Manufacturing

AbbVie has entered into a definitive agreement to acquire a drug-delivery device manufacturing facility and related intellectual property from West Pharmaceutical Services in Tempe, Arizona. The deal is designed to significantly enhance AbbVie’s in-house capacity for manufacturing drug-delivery systems, an increasingly critical component of advanced biologic and specialty medicines.

As part of the transaction, AbbVie plans to hire around 200 employees at the Arizona site and invest more than $175 million to purchase, upgrade, and integrate the facility into its global manufacturing network. This investment aligns with AbbVie’s broader strategy to expand pharmaceutical manufacturing within the United States, strengthen supply chain resilience, and improve patient access to innovative therapies.

"Over the next decade, AbbVie is investing more than $10 billion in capital to broadly support innovation and expand our manufacturing capabilities and capacity in the U.S.," said Robert A. Michael, chairman and chief executive officer, AbbVie. "With this investment, AbbVie is strengthening our manufacturing capabilities, ensuring we are well-positioned to develop and deliver next-generation medicines that make a remarkable impact on patients' lives."

The acquisition includes multiple production lines and 3.5 mL on-body injector technology, which will support the delivery of current and next-generation medicines across AbbVie’s immunology and neuroscience portfolios. These advanced delivery systems are particularly important for complex biologics that require precise, patient-friendly administration.

AbbVie already employs about 29,000 people across the U.S., including more than 6,000 at its 11 domestic manufacturing sites. Once completed, the transaction, expected to close in mid-2026, subject to customary conditions, will further expand AbbVie’s footprint and economic contribution in Arizona.